SAN DIEGO–(BUSINESS WIRE)–Biocom California, the association representing the California life science industry, issued the following statement regarding the drug pricing portion in the “Build Back Better” legislation. The statement can be attributed to Joe Panetta, Biocom California’s president and CEO: “On behalf of our more than 1,500 members across California, I am deeply concerned that the U.S. House of Representatives has decided to move forward with a drug pricing and access proposal th
Click here to view original post